cyrilzakka/clinical-trials huggingface dataset:
Effects of Music on Table Tennis Stroke Performance Among Mentally Fatigued University Players

The current study is going to investigate the music intervention on the table tennis stroke performance among table tennis stroke performance. The subjects will be instructed to listen to 3 minutes, which can facilitate the recovering process for scope of attention and thought-action repertoire. Thus, to see the improvement in stroke performance.

The intervention of this study is music, specifically, instruct subjects to listen inducing positive emotion music due to positive emotion benefit to cognition performance.

The condition of mental fatigue will be induced by Stroop task. Before the intervention or process of listening music, the pre-test will be recorded to compare the post-test value of table tennis stroke performance.

Moreover, the different music intervention will be implemented to identify the optimal selection.

Eligibility Criteria:
Inclusion Criteria:

* University table tennis players. 18-24 years.
* Both pen-holder and shake-hand play styles.
* At least played from the senior school.
* At least have 3 years' training experience.

Exclusion Criteria:

* Color blindness.
* Any disease or sleep disorder.
* Smoker or drunker
Respiratory Measurement of Volume Change Using Accelerometer, Thermographic Camera Electrical Impedance Tomography and Motion Correlation Analysis Using Mattress Sensor in Healthy Individuals

Tidal volume can be the most important technical indicator for ventilation. Measuring the volume of breathing can be used as an indicator of how effective a patient's gas exchange is, and as a predictive indicator of the statue of respiratory disease indirectly. These Tidal volumes can be measured using spirometry and pneumotachograph, and the breathing volume and the rate of airflow can directly or indirectly evaluate the lung function of the patient.

However, spirometry has limitations that patients who are difficult to measure, and that it is difficult to measure in bed. In this work, the movement of the thorax due to breathing is measured in a non-invasive manner (accelerometer, thermographic camera) and the accuracy is compared through changes in thoracic impedance obtained through Pulmovista 500. Furthermore, we would like to correlate the motion of the measured object through a mattress sensor.


Eligibility Criteria:
Inclusion Criteria:

1. over 19, under 50 years old and common BMI
2. non-smoking, person without cardiopulmonary disease.

Exclusion Criteria:

1. smoking, cardiopulmonary, infectious diseases.
Enhancing Social Connections Among Rural Community Members With Disordered Eating

This study is about testing a short program that uses social support to help people with disordered eating. The goal is to see if this program can help people build better habits and feel better about eating while reducing harmful symptoms. In the long run, this project wants to make it easier for people with eating problems to get help and recover, especially for those in rural areas or other groups who don't often get the care they need. Participants will complete self-report measures online, and complete a digital single-session program.


Eligibility Criteria:
Inclusion Criteria:

* Adult (18+ years old)
* disordered eating
* live in the United States of America

Exclusion Criteria:

* BMI below 18.5
Iron Fish in Dominican Republic (DR) Children

The objective of the study is to assess the acceptability, feasibility, and barriers to Lucky Iron Fish™ (LIF) utilization among families with young children in a Latin American community with a high prevalence of iron deficiency and iron-deficiency anemia.

.

The primary objective is to assess the acceptability of cooking with an iron ingot (Lucky Iron Fish™) compared to traditional oral iron supplementation methods among preschool aged children in a Dominican community with a high prevalence of anemia (\> 50%). Data will be collected to characterize the natural history of iron deficiency and anemia in pre-school aged children in a Dominican community. The study will involve a randomized control trial to assess the primary objective: children \> 1 year and \< 5 years of age will be randomized into two study arms: LIF plus citrus (LIF arm) versus standard iron-supplementation (enhanced standard of care). Participants enrolled in the both study arms will have study labs drawn every 3, 6, and 12-months (hemoglobin, serum ferritin, c-reactive protein) to assess the natural history of iron deficiency in these children. Concomitant to study labs, parents/guardians will be surveyed on acceptability, compliance, and barriers to use of their assigned iron supplementation method.

Primary study outcomes are the change in hemoglobin within the LIF group and then difference in change in hemoglobin between study arms over a 12-month study period. Secondary outcomes include changes in serum ferritin within and between study arms and exploring the relationship between changes in hemoglobin, serum ferritin, and C-reactive protein

Eligibility Criteria:
Inclusion Criteria:

* Parent/guardian ≥ 18 years of age
* Child \> 1 year and \< 5 years of age
* Child followed by Niños Primeros en Salud (NPS)
* Parent/guardian is Spanish speaking
* Parental/guardian permission is provided (informed consent)

Exclusion Criteria:

* Mother/Infant pairs enrolled in related protocol of this study
* Inability to understand and speak Spanish
* Severe cognitive impairment or severe psychiatric disease which would prohibit the answering of study questions
* Child followed by NPS malnutrition program
* Persons receiving pre-designed nutrient-fortified foods or participation in another nutrition program
* Child has documented sickle cell disease
Role of Acetaldehyde in the Development of Oral Cancer

This is a minimal risk intervention study where healthy volunteers and individuals with Fanconi anemia will consume a single dose of alcohol and provide primarily non-invasive biological samples at various time points. Biospecimens to be collected include saliva, oral cells collected via mouthwash and cheek brush, and urine. The collection of two blood samples (5 mL each) will be optional and banked for future use.


Eligibility Criteria:
Inclusion Criteria:

* 21-45 years of age for alcohol drinkers
* Occasionally consume alcohol
* At least 1 drink per month for healthy volunteers
* At least 1 drink in the last 3 months for Fanconi anemia patients
* Meets one of the three criteria
* Healthy volunteer - ALDH2\*1/1\* homozygotes-not of Eastern Asian decent;
* Healthy volunteer - ALDH2\*1/2\* heterozygotes-of Eastern Asian decent and experience flushing when drinking
* Individual's with Fanconi anemia (FA).
* 18-45 years of age for non-drinkers
* Never consume alcohol/not had alcohol in the last 6 months
* Healthy volunteers.
* Non-smoker (smoked \< 100 cigarettes in a lifetime)

Exclusion Criteria:

* Pregnant or nursing
* Taking any medication or drug that might affect alcohol use and absorption or that might be affected by alcohol consumption
* Healthy volunteers who have taken any antibiotics in the last 3 months
* Currently consuming more than 21 drinks per week
* Have any history of alcohol or drug related problems
* Current or former tobacco/nicotine product(s) user
* Any regular use of tobacco/nicotine products or marijuana in the last year (cigarettes, e-cigarettes, cigars, pipes, smokeless tobacco)
* "Trying" or limited use of any nicotine products or marijuana in the last 1 month
* Active infection (influenza, cold, COVID, respiratory / sinus infection) - admission in the study will be delayed pending improved health
* Non-FA volunteers who have an unstable medical condition or condition that could be affected by alcohol consumption (insulin-dependent diabetes, ulcers, heart issues)
* Experience severe adverse events (nausea, blacking out) when consuming even low doses of alcohol
A Professional Development Programme (ProDeveloP) for Newly Graduated Nurses

This clinical study aims to implement and evaluate a professional development programme (ProDeveloP) designed to facilitate the transition of newly graduated nurses (NGNs) into their new roles. NGNs face several challenges in the work environment and in developing their professional competencies. The aim is to support NGNs in a county hospital in central Sweden to facilitate their professional development. Data will be collected during the NGNs' first year through intensive longitudinal measures, including weekly and quarterly questionnaires. This will be combined with individual interviews and focus groups with NGNs, dialogue facilitators and managers.

The primary outcomes will be role clarity, task mastery, social acceptance, recovery and stress. The researchers will compare the results of the primary outcomes with those of a control group measure. Secondary outcomes will be experience of the intervention, transition support, job satisfaction and intention to leave.

Informed consent was signed prior to participation in the study. The ethical application has been approved by the Ethics Authority IS, diary number 2022-05682-0.

Eligibility Criteria:
Inclusion criteria:

* Registered nurses in Sweden employed as Newly Graduated Nurses (NGNs) in a county in central Sweden participating in the ProDeveloP, the intervention group.
* Registered nurses in Sweden employed as Newly Graduated Nurses (NGNs) in a county in central Sweden, NGNs participating in the introduction programme prior to the study, not participating in the ProDeveloP, the control group.
* Experienced registered nurses as facilitators for the dialogue groups for the NGNs in the intervention.
* Managers at the county hospital for the NGNs participating in the intervention.

Exclusion criteria:

• Managers without NGNs participated in the intervention.
A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache

The main purpose of this study is to assess the long-term safety and tolerability of galcanezumab administered up to once monthly in participants with episodic or chronic cluster headache who have completed study I5Q-MC-CGAL (NCT02397473) or study I5Q-MC-CGAM (NCT02438826).


Eligibility Criteria:
Inclusion Criteria:

* Participants who participated in and completed either study CGAL or study CGAM.
* Investigator judges the participant as reliable to follow all study procedures, keep all study visits, and be compliant with study requirements.

Exclusion Criteria:

* Current enrollment in or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device (with the exception of Study CGAL or Study CGAM).
* Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP) antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF) (with the exception of Study CGAL or Study CGAM).
* A history of migraine variants that could implicate or could be confused with ischemia.
* Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins.
* A history or presence of other medical illness that indicates a medical problem that would preclude study participation.
* Evidence of significant active or unstable psychiatric disease, in the opinion of the investigator.
* Women who are pregnant or nursing.
A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Following A Single Dose Of PF-04995274 In Healthy Adult Volunteers

The purpose of the study is to evaluate the safety and tolerability of PF-04995274 after administration of a single dose to healthy volunteers, and to evaluate the plasma drug concentrations after single dose in healthy volunteers.

The purpose is to evaluate the safety and pharmacokinetics of a single dose of PF-04995274 in healthy adult volunteers.

Eligibility Criteria:
Inclusion Criteria:

* For all cohorts, healthy male and/or female subjects of nonchildbearing potential between the ages of 18 and 55 years, inclusive. (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and heart rate measurement, 12 lead ECG and clinical laboratory tests).

Exclusion Criteria:

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
* Pregnant or nursing women; women of childbearing potential. Female subjects must be of non childbearing potential defined by a history of surgical sterilization (eg, hysterectomy or bilateral oophorectomy) or post menopausal status (complete absence of menses for at least two consecutive years) and elevated FSH concentration in women between 45 and 55.
Lactoferrin Versus Total Dose Infusion (TDI) For Treating Iron Deficiency Anemia in Pregnancy: Role of Nursing

This study consisted of 60 cases. All the cases of pregnant women are 4 months to 8 months of pregnancy. The cases divided into 30 pregnant women's were given iron supplementation without health education and another 30 were given iron supplementation and health education for comparison between them. Comparative between hemoglobin levels before and after medication. Treatment of iron deficiency anemia with iron supplementation received for one month.

The investigator will divide the participants into two groups e.g. group (A) and group (B) according to Hemoglobin level and receiving of oral supplementation for IDA accompanied with health education in case of group (A) and without health education in case of group (B). Then the investigator asked patient to sign the document of her investigations result to receive iron supplementation.

* After that, the investigator observes hemoglobin's Level, when it less than \>11g/dl, the patient will be the group (A) who will receive oral iron supplementation and health education.
* Group (B) who will receive Total Dose Infusion (TDI) without health education.

Eligibility Criteria:
Inclusion Criteria:

1. Pregnant Women aged \>18 years
2. Hemoglobin\<10g/dl
3. Gestational age between 14-28 weeks
4. Singleton pregnancy
5. Willingness to participate and signing the informed consent form

Exclusion Criteria:

1. Anemia predominantly caused by factors other than IDA (e.g. anemia with untreated B12 or foliate deficiency, hemolytic anemia),
2. Iron overload or disturbances in utilization of iron (e.g. hemochromatosis and haemosidrosis).
3. Decompensated liver cirrhosis and active hepatitis (ALAT\>3 times upper limit of normal).
4. Active acute or chronic infections (assessed by clinical judgment supplied with white Blood Cells (WBC) and C - reactive protein (CRP).
5. Rheumatoid arthritis with symptoms or signs of active inflammation.
6. Multiple allergies.
7. Known hypersensitivity to parental iron or any recipients in the investigational drug products.
8. Erythropoietin treatment within 8 weeks prior to the screening visit.
9. Other iron treatment within 8 weeks prior to the screening visit.
10. Planned elective surgery during the study.
11. Participation in any other clinical within 3 months prior to the screening.
12. Any other medical condition e.g. malignancy, uncontrolled hypertension, unstable ischemic heart disease, or uncontrolled diabetes mellitus.
Study Comparing Circular Stapler-assisted Colostomy vs Hand-stitching Colostomy of Colorectal Cancer Patients

Conventional hand-stitching colostomy involves extensive hand-stitching by the surgeon. There are significant variations in the outcome of surgery due to differences in the suture techniques of surgeons. The use of a circular stapler in colostomy seems more rapid and efficient colostomy than the conventional methods.But all those reports are single center retrospective cohort study，no randomized controlled trials have been carried out so far.The aim of this study is to comparing the safety and efficiency of circular stapler-assisted colostomy with conventional hand-stitching colostomy in patients with colorectal carcinoma.

It has been difficult to standardize the pull-out of the colon and the size, shape and sutures of the colostomy due to the different techniques employed and varying levels of skill of surgeons in different regions.Thus, various postoperative colostomy complications are inevitable after surgery. Surgeons have been looking for a simple and efficient way to standardize colostomy and reduce its complications.

So we want to compare the safety and efficiency of circular stapler-assisted colostomy with conventional hand-stitching colostomy in colorectal cancer patients.

Eligibility Criteria:
Inclusion Criteria:

* Receiving permanent colostomy because of colorectal cancer
* Age of ≥18 and ≤80

Exclusion Criteria:

* Not willing or incapable to comply with all study visits and assessments
* Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that puts the patient at high risk for treatment-related complications
A Prediction Model of Prolonged Mechanical Ventilation Following Acute Type A Aortic Dissection Surgery

The goal of this observational study is to develop and validate a predictive model for prolonged mechanical ventilation (PMV) following acute type A aortic dissection (ATAAD) surgery.

The main questions it aims to answer are:

1. To validate the predictive performance of the model for PMV after ATAAD surgery
2. To assess the proportion of PMV among patients undergoing ATAAD surgery
3. To evaluate the ICU length of stay and operative mortality in patients with PMV following ATAAD surgery


Eligibility Criteria:
Inclusion Criteria:

* Age ≥18 years;
* Diagnosis of acute type A aortic dissection (ATAAD) confirmed by computed tomography angiography and echocardiography;
* Patients who underwent aortic surgery requiring cardiopulmonary bypass (CPB), were admitted to the surgical intensive care unit (SICU), and received mechanical ventilation.

Exclusion Criteria:

* Reintubation;
* Intraoperative death or failure to survive beyond 72 hours postoperatively;
* Pregnancy;
* Severe comorbidities (e.g., lung cancer);
* Missing critical outcome data (e.g., short-term mortality, mechanical ventilation duration, reintubation).
Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment

A long-term 0.03% tacrolimus ointment based regimen comprising of up to 6 weeks of initial twice daily treatment and subsequent twice weekly prophylactic application can effectively treat active lesions of atopic dermatitis, and prevent, delay, and reduce flares.


Eligibility Criteria:
Inclusion Criteria:

* Male or female patient of any ethnic group
* Patient was at least 2-15 years old and suffered from mild to severe atopic dermatitis (Rajka/Langeland score of at least 3)

Exclusion Criteria:

* Patient had a genetic epidermal barrier defect such as Netherton's syndrome or generalised erythroderma
* Patient had a clinically significant skin infection on the affected (and to be treated) area
Dasatinib in Relapsed Chronic Lymphocytic Leukemia

The purpose of this research study is to see if Dasatinib is effective and safe to give to people with relapsed chronic lymphocytic leukemia (CLL) and to determine the effects of the drug on LYN kinase activity in blood and bone marrow. Recent research shows that a key enzyme in CLL cells is responsible for cell survival. This enzyme is called LYN kinase. Laboratory studies show that inhibition of LYN kinase in CLL cells results in the death to CLL cells. Dasatinib has the ability to inhibit LYN kinase and, therefore, should have some effect on CLL cells.

* After the screening procedures confirm that the participant is eligible and willing to participate in the research study, they will have the following tests and procedures.
* Dasatinib is given orally once daily. Each participant will have a pill diary to record doses and any missed doses. All necessary drug refills will be given during clinic appointments, at which time the pill diary and any unused study drug will be returned.
* During the first month of study treatment the participant will come to the clinic at the following intervals: Day 1: An EKG will be performed two hours after the first dose of medication; Days 3-8: Blood samples will be drawn once between days 3-8; Weeks 2-4: A physical examination, EKG and blood samples will be drawn once a week.
* Beginning with the second month of study treatment, participants will come to the clinic monthly for up to two years. The following tests and procedures will be done; physical examination (monthly), blood work (monthly), pregnancy test (monthly), EKG (monthly for 6 months, then when medically indicated), CT of the neck, chest and abdomen (every 2 months for 6 months, then once every 6 months), at the end of month 2, additional blood will be drawn for research testing.
* Participants can continue to take the study drug for up to two years as long as their disease does not progress and they are not experiencing any serious side effects.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* CLL/SLL with cells positive by flow cytometry (or immunostaining) for CD19, CD23 and CD. Patients may be CD23 negative as long as they are also cyclin D1 negative.
* Must have failed at least 1 prior fludarabine containing regimen or have failed at least 2 non-fludarabine containing regimens or have a contraindication to fludarabine use
* ECOG performance status of 2 or better
* Adequate organ function to tolerate chemotherapy
* Adequate method of contraception

Exclusion Criteria:

* Pregnant or breast-feeding women
* Uncontrolled angina within 3 months
* Diagnosed or suspected congenital long QT syndrome
* History of clinically significant ventricular arrhythmias
* Prolonged QTc interval on pre-entry electrocardiogram
* Uncontrolled hypertension
* Drugs that are generally accepted to have a risk of causing Torsades de Pointes
* Patient known to be HIV positive
* Known significant bleeding disorder unrelated to CLL
* Drugs that interfere with platelet function or coagulation must be stopped at least 7 days prior to entry
A Study on the Gastrointestinal Disease and Helicobacter Pylori Controlled Long Non-coding RNA

Helicobacter pylori (H.pylori) is a major human pathogenic bacterium in gastric mucosa which is linked to the development of gastritis, peptic ulcer disease, mucosa-associated lymphoid tissue lymphoma and gastric cancer. However the regulatory mechanism of H.pylori-induced immune response is not clear. Long non-coding RNA (lncRNA) has recently emerged as key post-transcriptional regulators of gene expression, differentiation. The investigators had a preliminary results which THRIL (TNFα and hnRNPL related immunoregulatory lincRNA) and PACER(p50-associated COX-2 extragenic RNA) played a potential role in H.pylori induced inflammatory cascade. However, there wasn't a previous study about expression of THRIL, PACER in a human tissue. Therefore, the investigators aimed to evaluate the expression of THRIL, PACER in patients with gastrointestinal disease according to H.pylori infection.


Eligibility Criteria:
Inclusion Criteria:

1. Over 19 years old
2. Patients with gastric ulcer
3. Patients with duodenal ulcer
4. Patients with stomach cancer
5. Patients with gastrointestinal discomfort symptoms

Exclusion Criteria:

1. Patients who has done helicobacter pylori eradication
2. Patients who has undergone gastrectomy
3. Patients who has undergone endoscopic submucosal dissection
4. Patients with active upper gastrointestinal bleeding